Preoperative BChE serves as a prognostic marker in patients with resectable AEG after neoadjuvant chemotherapy
Background Diminished systemic serum butyrylcholinesterase (BChE), a biomarker for chronic inflammation, cachexia, and advanced tumor stage, has shown to play a prognostic role in various malignancies. The aim of this study was to investigate the prognostic value of pretherapeutic BChE levels in pat...
Gespeichert in:
| Veröffentlicht in: | Langenbeck's archives of surgery 2023-06, Vol.408 (1), p.227-227, Article 227 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 227 |
|---|---|
| container_issue | 1 |
| container_start_page | 227 |
| container_title | Langenbeck's archives of surgery |
| container_volume | 408 |
| creator | Gensthaler, Lisa Jomrich, Gerd Brugger, Jonas Kollmann, Dagmar Paireder, Matthias Bologheanu, Milena Horn, Alexander Riegler, Franz M. Asari, Reza Schoppmann, Sebastian F. |
| description | Background
Diminished systemic serum butyrylcholinesterase (BChE), a biomarker for chronic inflammation, cachexia, and advanced tumor stage, has shown to play a prognostic role in various malignancies. The aim of this study was to investigate the prognostic value of pretherapeutic BChE levels in patients with resectable adenocarcinoma of the gastroesophageal junction (AEG), treated with or without neoadjuvant therapy.
Methods
Data of a consecutive series of patients with resectable AEG at the Department for General Surgery, Medical University of Vienna, were analyzed. Preoperative serum BChE levels were correlated to clinic-pathological parameters as well as treatment response. The prognostic impact of serum BChE levels on disease-free (DFS) and overall survival (OS) was evaluated by univariate and multivariate cox regression analysis, and Kaplan–Meier curves used for illustration.
Results
A total of 319 patients were included in this study, with an overall mean (standard deviation, SD) pretreatment serum BChE level of 6.22 (± 1.91) IU/L. In univariate models, diminished preoperative serum BChE levels were significantly associated with shorter overall (OS,
p
|
| doi_str_mv | 10.1007/s00423-023-02938-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10244274</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2823494522</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-9de6e7fc316b6f7e897dc871f31a218874a734ade81d89a3e75bc1c10e10ee783</originalsourceid><addsrcrecordid>eNp9kU1vGjEQhq0qVUNp_0AOkY-5bOMvsPcUEUTSSkjtoT1bxjvLLlnsje0F8e_jBIrSS6UZ2dI8fmfGL0JXlHyjhMjbSIhgvCBvWXJV7D-gERV8UjAxoRfv7pfoc4wbQshUluITuuSSKcKVGCH3K4DvIZjU7gDfz5sFjhB2ELHJgfvg187H1Fq8NeEJAm4d7jMMLkW8b1ODA0Swyaw6wLPFIzZ1ypQDb6rNsDMuYdvA1qcm9-gPX9DH2nQRvp7OMfrzsPg9_14sfz7-mM-WheWlSkVZwRRkbTmdrqa1BFXKyipJa04No0pJYSQXpgJFK1UaDnKystRSAjlAKj5Gd0fdflhtobJ53GA63Yc2r3HQ3rT634prG732O00JE4JJkRVuTgrBPw8Qk9620ULXmbzbEDVTjItSTBjLKDuiNvgYA9TnPpToV6f00SlN3jI7pff50fX7Cc9P_lqTAX4EYi65NQS98UNw-df-J_sChyaiNw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2823494522</pqid></control><display><type>article</type><title>Preoperative BChE serves as a prognostic marker in patients with resectable AEG after neoadjuvant chemotherapy</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Gensthaler, Lisa ; Jomrich, Gerd ; Brugger, Jonas ; Kollmann, Dagmar ; Paireder, Matthias ; Bologheanu, Milena ; Horn, Alexander ; Riegler, Franz M. ; Asari, Reza ; Schoppmann, Sebastian F.</creator><creatorcontrib>Gensthaler, Lisa ; Jomrich, Gerd ; Brugger, Jonas ; Kollmann, Dagmar ; Paireder, Matthias ; Bologheanu, Milena ; Horn, Alexander ; Riegler, Franz M. ; Asari, Reza ; Schoppmann, Sebastian F.</creatorcontrib><description>Background
Diminished systemic serum butyrylcholinesterase (BChE), a biomarker for chronic inflammation, cachexia, and advanced tumor stage, has shown to play a prognostic role in various malignancies. The aim of this study was to investigate the prognostic value of pretherapeutic BChE levels in patients with resectable adenocarcinoma of the gastroesophageal junction (AEG), treated with or without neoadjuvant therapy.
Methods
Data of a consecutive series of patients with resectable AEG at the Department for General Surgery, Medical University of Vienna, were analyzed. Preoperative serum BChE levels were correlated to clinic-pathological parameters as well as treatment response. The prognostic impact of serum BChE levels on disease-free (DFS) and overall survival (OS) was evaluated by univariate and multivariate cox regression analysis, and Kaplan–Meier curves used for illustration.
Results
A total of 319 patients were included in this study, with an overall mean (standard deviation, SD) pretreatment serum BChE level of 6.22 (± 1.91) IU/L. In univariate models, diminished preoperative serum BChE levels were significantly associated with shorter overall (OS,
p
< 0.003) and disease-free survival (DFS,
p
< 0.001) in patients who received neoadjuvant treatment and/or primary resection. In multivariated analysis, decreased BChE was significantly associated with shorter DFS (HR: 0.92, 95% CI: 0.84–1.00,
p
0.049) and OS (HR: 0.92, 95% CI: 0.85–1.00,
p
< 0.49) in patients receiving neoadjuvant therapy. Backward regression identified the interaction between preoperative BChE and neoadjuvant chemotherapy as a predictive factor for DFS and OS.
Conclusion
Diminished serum BChE serves as a strong, independent, and cost-effective prognostic biomarker for worse outcome in patients with resectable AEG who had received neoadjuvant chemotherapy.</description><identifier>ISSN: 1435-2451</identifier><identifier>ISSN: 1435-2443</identifier><identifier>EISSN: 1435-2451</identifier><identifier>DOI: 10.1007/s00423-023-02938-w</identifier><identifier>PMID: 37280384</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Abdominal Surgery ; Biomarkers ; Butyrylcholinesterase ; Cardiac Surgery ; General Surgery ; Humans ; Medicine ; Medicine & Public Health ; Multivariate Analysis ; Neoadjuvant Therapy ; Prognosis ; Retrospective Studies ; Thoracic Surgery ; Traumatic Surgery ; Vascular Surgery</subject><ispartof>Langenbeck's archives of surgery, 2023-06, Vol.408 (1), p.227-227, Article 227</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c398t-9de6e7fc316b6f7e897dc871f31a218874a734ade81d89a3e75bc1c10e10ee783</cites><orcidid>0000-0002-1725-7086</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00423-023-02938-w$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00423-023-02938-w$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,777,781,882,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37280384$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gensthaler, Lisa</creatorcontrib><creatorcontrib>Jomrich, Gerd</creatorcontrib><creatorcontrib>Brugger, Jonas</creatorcontrib><creatorcontrib>Kollmann, Dagmar</creatorcontrib><creatorcontrib>Paireder, Matthias</creatorcontrib><creatorcontrib>Bologheanu, Milena</creatorcontrib><creatorcontrib>Horn, Alexander</creatorcontrib><creatorcontrib>Riegler, Franz M.</creatorcontrib><creatorcontrib>Asari, Reza</creatorcontrib><creatorcontrib>Schoppmann, Sebastian F.</creatorcontrib><title>Preoperative BChE serves as a prognostic marker in patients with resectable AEG after neoadjuvant chemotherapy</title><title>Langenbeck's archives of surgery</title><addtitle>Langenbecks Arch Surg</addtitle><addtitle>Langenbecks Arch Surg</addtitle><description>Background
Diminished systemic serum butyrylcholinesterase (BChE), a biomarker for chronic inflammation, cachexia, and advanced tumor stage, has shown to play a prognostic role in various malignancies. The aim of this study was to investigate the prognostic value of pretherapeutic BChE levels in patients with resectable adenocarcinoma of the gastroesophageal junction (AEG), treated with or without neoadjuvant therapy.
Methods
Data of a consecutive series of patients with resectable AEG at the Department for General Surgery, Medical University of Vienna, were analyzed. Preoperative serum BChE levels were correlated to clinic-pathological parameters as well as treatment response. The prognostic impact of serum BChE levels on disease-free (DFS) and overall survival (OS) was evaluated by univariate and multivariate cox regression analysis, and Kaplan–Meier curves used for illustration.
Results
A total of 319 patients were included in this study, with an overall mean (standard deviation, SD) pretreatment serum BChE level of 6.22 (± 1.91) IU/L. In univariate models, diminished preoperative serum BChE levels were significantly associated with shorter overall (OS,
p
< 0.003) and disease-free survival (DFS,
p
< 0.001) in patients who received neoadjuvant treatment and/or primary resection. In multivariated analysis, decreased BChE was significantly associated with shorter DFS (HR: 0.92, 95% CI: 0.84–1.00,
p
0.049) and OS (HR: 0.92, 95% CI: 0.85–1.00,
p
< 0.49) in patients receiving neoadjuvant therapy. Backward regression identified the interaction between preoperative BChE and neoadjuvant chemotherapy as a predictive factor for DFS and OS.
Conclusion
Diminished serum BChE serves as a strong, independent, and cost-effective prognostic biomarker for worse outcome in patients with resectable AEG who had received neoadjuvant chemotherapy.</description><subject>Abdominal Surgery</subject><subject>Biomarkers</subject><subject>Butyrylcholinesterase</subject><subject>Cardiac Surgery</subject><subject>General Surgery</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multivariate Analysis</subject><subject>Neoadjuvant Therapy</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Thoracic Surgery</subject><subject>Traumatic Surgery</subject><subject>Vascular Surgery</subject><issn>1435-2451</issn><issn>1435-2443</issn><issn>1435-2451</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kU1vGjEQhq0qVUNp_0AOkY-5bOMvsPcUEUTSSkjtoT1bxjvLLlnsje0F8e_jBIrSS6UZ2dI8fmfGL0JXlHyjhMjbSIhgvCBvWXJV7D-gERV8UjAxoRfv7pfoc4wbQshUluITuuSSKcKVGCH3K4DvIZjU7gDfz5sFjhB2ELHJgfvg187H1Fq8NeEJAm4d7jMMLkW8b1ODA0Swyaw6wLPFIzZ1ypQDb6rNsDMuYdvA1qcm9-gPX9DH2nQRvp7OMfrzsPg9_14sfz7-mM-WheWlSkVZwRRkbTmdrqa1BFXKyipJa04No0pJYSQXpgJFK1UaDnKystRSAjlAKj5Gd0fdflhtobJ53GA63Yc2r3HQ3rT634prG732O00JE4JJkRVuTgrBPw8Qk9620ULXmbzbEDVTjItSTBjLKDuiNvgYA9TnPpToV6f00SlN3jI7pff50fX7Cc9P_lqTAX4EYi65NQS98UNw-df-J_sChyaiNw</recordid><startdate>20230606</startdate><enddate>20230606</enddate><creator>Gensthaler, Lisa</creator><creator>Jomrich, Gerd</creator><creator>Brugger, Jonas</creator><creator>Kollmann, Dagmar</creator><creator>Paireder, Matthias</creator><creator>Bologheanu, Milena</creator><creator>Horn, Alexander</creator><creator>Riegler, Franz M.</creator><creator>Asari, Reza</creator><creator>Schoppmann, Sebastian F.</creator><general>Springer Berlin Heidelberg</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1725-7086</orcidid></search><sort><creationdate>20230606</creationdate><title>Preoperative BChE serves as a prognostic marker in patients with resectable AEG after neoadjuvant chemotherapy</title><author>Gensthaler, Lisa ; Jomrich, Gerd ; Brugger, Jonas ; Kollmann, Dagmar ; Paireder, Matthias ; Bologheanu, Milena ; Horn, Alexander ; Riegler, Franz M. ; Asari, Reza ; Schoppmann, Sebastian F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-9de6e7fc316b6f7e897dc871f31a218874a734ade81d89a3e75bc1c10e10ee783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Abdominal Surgery</topic><topic>Biomarkers</topic><topic>Butyrylcholinesterase</topic><topic>Cardiac Surgery</topic><topic>General Surgery</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multivariate Analysis</topic><topic>Neoadjuvant Therapy</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Thoracic Surgery</topic><topic>Traumatic Surgery</topic><topic>Vascular Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gensthaler, Lisa</creatorcontrib><creatorcontrib>Jomrich, Gerd</creatorcontrib><creatorcontrib>Brugger, Jonas</creatorcontrib><creatorcontrib>Kollmann, Dagmar</creatorcontrib><creatorcontrib>Paireder, Matthias</creatorcontrib><creatorcontrib>Bologheanu, Milena</creatorcontrib><creatorcontrib>Horn, Alexander</creatorcontrib><creatorcontrib>Riegler, Franz M.</creatorcontrib><creatorcontrib>Asari, Reza</creatorcontrib><creatorcontrib>Schoppmann, Sebastian F.</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Langenbeck's archives of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gensthaler, Lisa</au><au>Jomrich, Gerd</au><au>Brugger, Jonas</au><au>Kollmann, Dagmar</au><au>Paireder, Matthias</au><au>Bologheanu, Milena</au><au>Horn, Alexander</au><au>Riegler, Franz M.</au><au>Asari, Reza</au><au>Schoppmann, Sebastian F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preoperative BChE serves as a prognostic marker in patients with resectable AEG after neoadjuvant chemotherapy</atitle><jtitle>Langenbeck's archives of surgery</jtitle><stitle>Langenbecks Arch Surg</stitle><addtitle>Langenbecks Arch Surg</addtitle><date>2023-06-06</date><risdate>2023</risdate><volume>408</volume><issue>1</issue><spage>227</spage><epage>227</epage><pages>227-227</pages><artnum>227</artnum><issn>1435-2451</issn><issn>1435-2443</issn><eissn>1435-2451</eissn><abstract>Background
Diminished systemic serum butyrylcholinesterase (BChE), a biomarker for chronic inflammation, cachexia, and advanced tumor stage, has shown to play a prognostic role in various malignancies. The aim of this study was to investigate the prognostic value of pretherapeutic BChE levels in patients with resectable adenocarcinoma of the gastroesophageal junction (AEG), treated with or without neoadjuvant therapy.
Methods
Data of a consecutive series of patients with resectable AEG at the Department for General Surgery, Medical University of Vienna, were analyzed. Preoperative serum BChE levels were correlated to clinic-pathological parameters as well as treatment response. The prognostic impact of serum BChE levels on disease-free (DFS) and overall survival (OS) was evaluated by univariate and multivariate cox regression analysis, and Kaplan–Meier curves used for illustration.
Results
A total of 319 patients were included in this study, with an overall mean (standard deviation, SD) pretreatment serum BChE level of 6.22 (± 1.91) IU/L. In univariate models, diminished preoperative serum BChE levels were significantly associated with shorter overall (OS,
p
< 0.003) and disease-free survival (DFS,
p
< 0.001) in patients who received neoadjuvant treatment and/or primary resection. In multivariated analysis, decreased BChE was significantly associated with shorter DFS (HR: 0.92, 95% CI: 0.84–1.00,
p
0.049) and OS (HR: 0.92, 95% CI: 0.85–1.00,
p
< 0.49) in patients receiving neoadjuvant therapy. Backward regression identified the interaction between preoperative BChE and neoadjuvant chemotherapy as a predictive factor for DFS and OS.
Conclusion
Diminished serum BChE serves as a strong, independent, and cost-effective prognostic biomarker for worse outcome in patients with resectable AEG who had received neoadjuvant chemotherapy.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>37280384</pmid><doi>10.1007/s00423-023-02938-w</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-1725-7086</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1435-2451 |
| ispartof | Langenbeck's archives of surgery, 2023-06, Vol.408 (1), p.227-227, Article 227 |
| issn | 1435-2451 1435-2443 1435-2451 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10244274 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Abdominal Surgery Biomarkers Butyrylcholinesterase Cardiac Surgery General Surgery Humans Medicine Medicine & Public Health Multivariate Analysis Neoadjuvant Therapy Prognosis Retrospective Studies Thoracic Surgery Traumatic Surgery Vascular Surgery |
| title | Preoperative BChE serves as a prognostic marker in patients with resectable AEG after neoadjuvant chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T03%3A57%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preoperative%20BChE%20serves%20as%20a%20prognostic%20marker%20in%20patients%20with%20resectable%20AEG%20after%20neoadjuvant%20chemotherapy&rft.jtitle=Langenbeck's%20archives%20of%20surgery&rft.au=Gensthaler,%20Lisa&rft.date=2023-06-06&rft.volume=408&rft.issue=1&rft.spage=227&rft.epage=227&rft.pages=227-227&rft.artnum=227&rft.issn=1435-2451&rft.eissn=1435-2451&rft_id=info:doi/10.1007/s00423-023-02938-w&rft_dat=%3Cproquest_pubme%3E2823494522%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2823494522&rft_id=info:pmid/37280384&rfr_iscdi=true |